Peking University Study Identifies Liver Cancer Immune Microenvironment Subtypes
Researchers at Peking University have uncovered several subtypes in the tumor immune microenvironment (TIME) relevant...
Cancer
Luye Pharma’s Biosimilar LY06006/BA6101 Approved for Osteoporosis Treatment
China-based Luye Pharma Group (HKG: 2186) has announced that it has received market approval from...
CStone’s PD-L1 Inhibitor Sugemalimab Achieves Primary Endpoint in Gastric Cancer Study
China-based CStone Pharmaceuticals (HKG: 2616) has announced that its GEMSTONE-303 study for the programmed death-ligand...
BeiGene’s Brukinsa Receives Marketing Approval in Brazil
China-based biotech BeiGene Inc. (HKG: 6160, SHA: 688235, NASDAQ: BGNE) has announced that it has...
Fujian Cosunter Receives Multiple Patents for Cancer and Hepatitis Drugs
China-based Fujian Cosunter Pharmaceutical Co., Ltd (SHE: 300436) has announced the receipt of multiple patents...
LianBio Initiates Phase I Study of SHP2 Inhibitor BBP-398 in China
Sino-US biotech LianBio has announced the first patient dosing in a Phase I clinical study...
Ascentage Pharma Gains CDE Approval for Phase I Study of APG-5918
Suzhou-based Ascentage Pharma (HKG: 6855) has announced that it has received approval from the Center...
Betta Pharmaceuticals’ BPI-D0316 Shows Promise in Phase II/III Lung Cancer Study
China-based Betta Pharmaceuticals Co., Ltd (SHE: 300558) has announced the summary report of a Phase...
Cowell Health Partners with AstraZeneca to Enhance Cancer Care at CIIE
Cowell Health has announced a partnership with UK-based AstraZeneca (AZ, NASDAQ: AZN) at the 5th...
Adicon Partners with Illumina to Advance Oncology Detection Assay TSO 500
China-based Adicon Holdings Limited has announced a strategic partnership with US-based Illumina (NASDAQ: ILMN) at...
Pfizer Partners with China Cardiovascular Association to Tackle Heart Failure
US-based Pfizer (NYSE: PFE) has initiated a strategic partnership with the China Cardiovascular Association (CCA),...
Cyramza Prescribed in China for Advanced Gastric Cancer
Cyramza (ramucirumab) was first prescribed on November 6, 2022, at the Zhongshan Hospital in Shanghai...
Merck’s Keytruda Receives 10th Indication Approval in China for TNBC
US-based Merck Sharp & Dohme’s (MSD, NYSE: MRK) programmed death-1 (PD-1) inhibitor Keytruda (pembrolizumab) has...
PingAn Good Doctor Partners with Roche and OrigiMed at CIIE
The 5th China International Import Expo (CIIE) saw China-based Ping An Healthcare and Technology Co.,...
Qilu Pharma’s QL1706 Shows Promise in Phase II Cervical Cancer Study
China-based Qilu Pharmaceutical has published the latest results from a Phase II clinical study for...
Eli Lilly Partners with AmoyDx and Burning Rock for Retevmo Companion Diagnostics
The 5th China International Import Expo (CIIE) saw US-based Eli Lilly (NYSE: LLY) announce a...
CIIE: MET HER2 Precision Diagnosis Alliance Formed to Advance Lung Cancer Treatment
The 5th China International Import Expo (CIIE) witnessed the establishment of the MET HER2 precision...
Jiangsu Yahong Initiates Phase III Study for Hexvix in Bladder Cancer Detection
China-based urogenital cancer specialist Jiangsu Yahong Meditech Co., Ltd (Asieris, SHA: 688176) has announced the...
Betta Pharmaceuticals’ BPI-452080 Accepted for Review by NMPA
China’s Betta Pharmaceuticals (SHE: 300558) has announced that a clinical trial filing for its Category...